US Patent

US12403099 — Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof

Formulation · Assigned to Impax Laboratories LLC · Expires 2034-10-07 · 8y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a controlled-release oral solid formulation of levodopa and/or its esters, combined with a decarboxylase inhibitor.

USPTO Abstract

The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.

Drugs covered by this patent

Patent Metadata

Patent number
US12403099
Jurisdiction
US
Classification
Formulation
Expires
2034-10-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.